-

Toku welcomes Dr Robert Weinreb to Board of Directors

original Dr Robert Weinreb has joined Toku Inc.'s board of directors (Photo: Business Wire)

Dr Robert Weinreb has joined Toku Inc.'s board of directors (Photo: Business Wire)

SAN DIEGO--(BUSINESS WIRE)--Toku is pleased to announce the appointment of Robert N. Weinreb MD to its Board of Directors. Renowned globally for his contributions to ophthalmology, Dr. Weinreb's appointment underscores Toku's commitment to excellence and innovation in eye care. “We are thrilled to welcome Dr. Weinreb to our Board! Working with him, we will accelerate our leadership in healthcare through the eye,” according to Ehsan Vaghefi, President and CEO.

Dr. Weinreb's distinguished career encompasses groundbreaking research and clinical practice. As the Chair and Distinguished Professor of Ophthalmology at the University of California, San Diego, and Director of the Shiley Eye Institute and the Hamilton Glaucoma Center. This week it was announced that Dr Weinreb joined the Ophthalmologist Power List Hall of Fame. He brings unparalleled expertise to the Toku board. “I am excited to join Toku's Board of Directors. The company's groundbreaking work is certain to have a meaningful impact on the lives of patients throughout the world,” comments Dr. Weinreb.

About Toku, Inc.

Toku, Inc. is a cutting-edge technology company that specializes in developing non-invasive, AI-powered diagnostic and screening tools using retinal imaging to measure cardiovascular and other health risk factors. The company’s first commercialized product, BioAge, analyzes biometric markers visible in the retinal image to accurately measure an individual’s biological age. The test can provide a detailed report on an individual’s overall health. The Company is also developing the CLAiR platform, an AI-powered technology to assess cardiovascular risk by means of retinal photographs of the back of the eye. The CLAiR platform has received Breakthrough Device designation from the FDA in November 2023 and CE & UKCA Marks in 2024. MyKidneyAI is the latest in Toku’s suite of products. Toku is committed to making its technology widely accessible through its major partnerships across the world. The company’s technology is built on the latest research in AI, and its team of experts includes leading scientists and medical professionals.

Contacts

Media
Francesca Logan
Francesca.logan@tokueyes.com

Industry:

Toku, Inc.

Release Versions
English

Contacts

Media
Francesca Logan
Francesca.logan@tokueyes.com

More News From Toku, Inc.

Toku Inc. Secures FDA Breakthrough Designation for Technology that Identifies Chronic Kidney Disease Risk Through the Eye

SAN DIEGO--(BUSINESS WIRE)--Toku, Inc., a commercial medical device company specializing in imaging technology and AI, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation to its MyKidneyAI technology. MyKidneyAI uses AI to analyze retinal images collected at routine eye exams to detect elevated chronic kidney disease (CKD) risk in people with diabetes. Most people with diabetes are not routinely screened for CKD today, resulting in the di...

Toku Appoints Former Google Head of Cardiovascular Health as Chief Health Officer

SAN DIEGO--(BUSINESS WIRE)--Toku is delighted to announce the appointment of Professor Michael V. McConnell, MD, MSEE to the role of Chief Health Officer. Professor McConnell’s former roles include Director of Advanced Cardiovascular Imaging and Preventive Cardiology at Stanford University and Head of Cardiovascular Health Innovations at Google. He is also a founding member of the American Heart Association’s Health Tech Advisory Group and author of Fight Heart Disease Like Cancer. Professor Mc...

Toku Obtains CE and UKCA Marks for AI Cardiovascular Risk Assessments Through the Eye

SAN DIEGO--(BUSINESS WIRE)--Toku, Inc., a commercial medical device company specializing in AI assessment of retinal images, announced today that it has obtained CE and UKCA Marks for its patented CLAiR technology. This significant milestone underscores Toku’s commitment to maintaining the highest standards of quality and safety and allows access to the Europe and United Kingdom markets. CLAiR provides accurate, affordable, non-invasive evaluation for the risk of cardiovascular disease (CVD) at...
Back to Newsroom